title: Effects of IL-17A on the occurrence of lung adenocarcinoma.
abstract: The relationship between IL-17A and cancer, whether beneficial or antagonistic, continues to be a controversial issue. In this study, effects of IL-17A on lung adenocarcinoma were investigated using lung cancer cell lines, 95D and 95C. In the presence or absence of IL-17A, cell proliferation and VEGF secretion were detected. Effects of IL-17A on capillary networks and process of angiogenesis were also evaluated. In vivo, the level of IL-17A was assayed in the serum of lung adenocarcinoma patients. At the same time, slices of adenocarcinoma tissue were analyzed for expression of IL-17A, its receptor (IL-17RA), VEGF, CD4(+)-IL-17A+ cells and CD8(+)-IL-17A+ cells by immunohistochemistry and immunofluorescence assays. IL-17A did not have effect on the proliferation of 95D or 95C cells, however, the elevated expression of VEGF in supernatant of 95D or 95C cells was found to be IL-17A concentration-dependent. Supernatants from 95D or 95C cells treated with IL-17A could obviously facilitate angiogenesis, compared with IL-17A absence group (P < 0.01). Higher levels of IL-17A were detected in serum of patients with lung adenocarcinoma than healthy controls (P < 0.001). Higher positive expressions of IL-17A, IL-17RA and VEGF were confirmed in lung adenocarcinoma lesion tissues compared to pericancerous normal tissues (P < 0.001). Tnc17 cells, as well as Th17 cells were found in adenocarcinoma tissue, indicating a potential role of these cells in disease. In summary, IL-17A might affect lung adenocarcinoma by promoting angiogenesis, while the role of Tnc17 cells or Th17 cells remains to be elucidated.
authors.affiliation: Department of Oncology, First Affiliated Clinic College of Harbin Medical University, Harbin, China.
authors.forename: Ying
authors.initials: Y
authors.lastname: Li
authors.forename: Zhen Yuan
authors.initials: ZY
authors.lastname: Cao
authors.forename: Bo
authors.initials: B
authors.lastname: Sun
authors.forename: Guang You
authors.initials: GY
authors.lastname: Wang
authors.forename: Zheng
authors.initials: Z
authors.lastname: Fu
authors.forename: Yu Mei
authors.initials: YM
authors.lastname: Liu
authors.forename: Qing Fei
authors.initials: QF
authors.lastname: Kong
authors.forename: Jing Hua
authors.initials: JH
authors.lastname: Wang
authors.forename: Yao
authors.initials: Y
authors.lastname: Zhang
authors.forename: Xiang Ying
authors.initials: XY
authors.lastname: Xu
authors.forename: Hu Lun
authors.initials: HL
authors.lastname: Li
mesh_terms: D000230:Adenocarcinoma / Q000188:drug therapy / Q000378:metabolism* / Q000473:pathology; D000077192:Adenocarcinoma of Lung; D000328:Adult; D000368:Aged; D015704:CD4 Antigens / Q000378:metabolism; D016827:CD8 Antigens / Q000378:metabolism; D045744:Cell Line, Tumor; D049109:Cell Proliferation; D042783:Endothelial Cells / Q000187:drug effects / Q000473:pathology; D005260:Female; D006801:Humans; D020381:Interleukin-17 / Q000097:blood / Q000378:metabolism* / Q000494:pharmacology; D008175:Lung Neoplasms / Q000188:drug therapy / Q000378:metabolism* / Q000473:pathology; D008297:Male; D008875:Middle Aged; D009389:Neovascularization, Pathologic / Q000139:chemically induced; D053722:Receptors, Interleukin-17 / Q000378:metabolism; D012016:Reference Values; D042461:Vascular Endothelial Growth Factor A / Q000378:metabolism
chemical_list: D015704:CD4 Antigens; D016827:CD8 Antigens; C508717:IL17A protein, human; C109985:IL17RA protein, human; D020381:Interleukin-17; D053722:Receptors, Interleukin-17; C467484:VEGFA protein, human; D042461:Vascular Endothelial Growth Factor A